关于江苏联环药业股份有限公司股票交易 异常波动询证函的回复 我公司在本次股票异常波动期间未买卖联环药业股票。 江苏联环药业集团有限公司 江苏联环药业股份有限公司: 《江苏联环药业股份有限公司关于公司股票交易异常 波动的询证函》收悉,经自查确认,现回复如下: 我公司作为江苏联环药业股份有限公司（以下简称"联" 环药业")的控股股东,截至目前,除联环药业在指定媒体 已披露信息之外,我公司不存在影响联环药业股票价格异常 波动的重大事项;不存在应披露而未披露的重大信息,包括 但不限于重大资产重组、股份发行、上市公司收购、债务重 组、业务重组、资产剥离、资产注入、股份回购、股权激励、 引进战略投资者等重大事项。 同时,经与扬州市国有资产监督管理委员会(以下简称 "扬州市国资委")确认,截至目前,扬州市国资委作为联 环药业的实际控制人,除联环药业在指定媒体已披露信息之 外,扬州市国资委不存在影响联环药业股票价格异常波动的 重大事项;不存在应披露而未披露的重大信息,包括但不限 于重大资产重组、股份发行、上市公司收购、债务重组、业 务重组、资产剥离、资产注入、股份回购、股权激励、引进 战略投资者等重大事项。 我公司亦将严格遵 ...

Core Viewpoint - The National Market Supervision Administration of China has imposed administrative penalties on four pharmaceutical companies for engaging in a monopoly agreement, resulting in a total fine exceeding 362 million yuan [1][2]. Group 1: Companies Involved - The companies involved in the monopoly agreement are Tianjin Pharmaceutical Industry Co., Ltd. (津药药业), Zhejiang Xianju Pharmaceutical Co., Ltd. (仙琚制药), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (联环药业), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd. (国康瑞金制药) [1]. - Among these, Lianhuan Pharmaceutical, Tianjin Pharmaceutical, and Xianju Pharmaceutical hold the approval for the injection of dexamethasone phosphate sodium and have undergone consistency evaluation [2]. Group 2: Penalties and Financial Impact - The total fines imposed include 500,000 yuan on the individual responsible, confiscation of illegal gains, and an 8% fine on the previous year's sales for the four companies, amounting to approximately 355 million yuan [2]. - For Lianhuan Pharmaceutical, the penalty represents 2.83% of the company's audited revenue and 72.53% of the net profit attributable to shareholders for the most recent fiscal year [2]. - The penalty will reduce the net profit attributable to shareholders for Lianhuan Pharmaceutical by approximately 61.0382 million yuan for the fiscal year 2025 [2]. Group 3: Market Impact - The companies coordinated to raise the price of dexamethasone phosphate sodium from 8,000 yuan per kilogram to 13,000 yuan between February 2022 and March 2024, significantly restricting market competition and increasing healthcare costs for consumers [1].

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has shown a significant stock price increase and strong revenue growth, indicating a positive market response and operational performance despite a decline in net profit [1] Company Overview - Jiangsu Lianhuan Pharmaceutical is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise [1] - The company integrates research and development, production, and sales, specializing in various pharmaceutical forms including tablets, hard capsules, suppositories, and granules, with an annual production capacity of 5 billion units [1] - Its main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, featuring over 100 varieties, including key products like the first-class new drug Aipulete and second-class new drug Ebastine [1] - The company boasts a high-end R&D team of nearly 200 members and multiple research platforms [1] Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 628 million yuan, representing a year-on-year growth of 18.78% [1] - However, the net profit attributable to shareholders was 23.06 million yuan, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders was 30,300, with an average of 9,416 circulating shares per person [1] Market Activity - On August 12, the company's stock price increased by 6.13%, reaching 25.44 yuan per share, with a trading volume of 926 million yuan and a turnover rate of 13.25% [1] - The total market capitalization of Jiangsu Lianhuan Pharmaceutical is 7.262 billion yuan [1]

Meeting Overview - The first temporary shareholders' meeting of Jiangsu Lianhuan Pharmaceutical Co., Ltd. was held on August 11, 2025, at the company's conference room in Yangzhou [2] - The meeting was legally convened and presided over by Chairman Qian Zhenhua, utilizing a combination of on-site and online voting methods [2][3] Resolutions Passed - The following resolutions were approved during the meeting: 1. Election of Ms. Wu Fang as an independent director [4] 2. Proposal for the company to issue technology innovation bonds [4] - All current directors and supervisors were present during the voting process [4] Legal Verification - The meeting was witnessed by Beijing Zhonglun (Chengdu) Law Firm, confirming that the convening and voting procedures complied with relevant laws and regulations [6] Committee Adjustments - Following the election of a new independent director, adjustments were made to the members of the Audit Committee and the Nomination Committee: 1. Audit Committee: Changed from Zhang Bin (convener), Chen Ying, Tu Bin to Zhang Bin (convener), Wu Fang, Tu Bin [9] 2. Nomination Committee: Changed from Hu Yiqiao (convener), Chen Ying, Qian Zhenhua to Hu Yiqiao (convener), Wu Fang, Qian Zhenhua [9]

证券代码：600513 证券简称：联环药业 公告编号：2025-055 江苏联环药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 8 月 11 日 | | 议案名称 | | | | | | 比例 | | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | | 票数 | 比例（%） | 票数 | 比例（%） | 票数 | | | | | | | | | （%） | | 《关于选举吴方女士为 (二)股东会召开的地点：扬州生物健康产业园健康一路 9 号联环药业会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议经过适当的召集和通知程序，由公司董事长钱振华先生主持，采用 了现场投票与网络投票相结合的表决方式，符合《中华人民共和国公司法》、中 国证监会《 ...

（文章来源：证券日报） 证券日报网讯 8月11日晚间，联环药业发布公告称，公司2025年第一次临时股东会于2025年8月11日召 开，审议通过了《关于公司拟发行科技创新债券的议案》等。 ...

New Stock Issuance - Hongyuan Co., Ltd. (stock code: 920018) issued shares at a price of 9.17 on August 11, 2025[1] - China Shipbuilding Industry Corporation (stock code: 600150) has a cash acquisition request period from August 13 to August 15, 2025[1] - ST Kelly (stock code: 300326) has a tender offer period from July 17 to August 15, 2025[1] Rights and Announcements - China Heavy Industry (stock code: 601989) has a cash option declaration period starting August 13, 2025[1] - Fushun Special Steel (stock code: 600399) has a tender offer period from August 12 to September 10, 2025[1] - North Long Dragon (stock code: 301357) has an announcement link for further details[1] Market Volatility - Several stocks, including ST Xifa (stock code: 000752) and ST Aowei (stock code: 002231), are under observation for significant price fluctuations[1] - The report highlights abnormal fluctuations in stocks such as ST Songfa (stock code: 603268) and ST Yancheng (stock code: 603063)[2]

Core Viewpoint - The pharmaceutical and biotechnology sectors are experiencing mixed performance, with innovative drug stocks showing significant volatility and a shift in market sentiment towards weight loss medications, particularly in the context of recent earnings reports and clinical trial data [3][10][11]. Group 1: Market Performance - The pharmaceutical and biotechnology index fell by 0.10%, slightly outperforming the Shanghai Composite Index by 0.02 percentage points [3]. - Among 140 innovative drug stocks in A-shares, only 34 saw an increase, a decrease of 72 from the previous week, indicating a notable pullback [4]. - In Hong Kong, 39 innovative drug stocks were tracked, with 22 experiencing gains, suggesting a relatively better performance compared to A-shares [4]. Group 2: Notable Stock Movements - In A-shares, Lianhuan Pharmaceutical led with a 31.41% increase, attributed to its LH-1801 project still in the R&D phase [5]. - Conversely, Yifang Bio saw a significant decline of 16.91% due to a large discounted block trade [5]. - In Hong Kong, Gilead Sciences-B experienced a 30.29% increase, reflecting strong market interest [6]. Group 3: IPO Developments - Guangzhou Yinnuo Pharmaceutical Group has initiated its IPO process, expecting to list on the Hong Kong Stock Exchange on August 15, with plans to issue 36.56 million H-shares at a price of HKD 18.68 per share [8][9]. - The company focuses on metabolic diseases and has a core product, Eisuparaglutide α, approved for type 2 diabetes treatment, with projected sales of HKD 38.14 million in the first five months of 2025 [8]. Group 4: Weight Loss Drug Market Dynamics - Major players in the weight loss drug market, such as Eli Lilly and Novo Nordisk, have seen significant market cap losses due to disappointing clinical data, with Eli Lilly losing USD 130 billion in a week [10][11]. - Despite the downturn for these companies, the overall market for weight loss drugs remains robust, with innovative products from Chinese companies gaining traction [11][12]. - New entrants in the GLP-1 drug market are focusing on improved efficacy and safety profiles, aiming to meet diverse patient needs [11][12]. Group 5: Industry Insights - The innovative drug sector in China is transitioning from a follower to a leader in global drug development, with a significant share of new drug transactions [17][18]. - The industry faces challenges such as market entry efficiency and the need for mechanisms that reward innovation, which are critical for sustaining growth and avoiding market saturation [18][20].

证券代码：600513 证券简称：联环药业 公告编号：2025—056 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于 2025 年 8 月 11 日召开 第九届董事会第十三次临时会议，审议通过了《关于调整公司各专门委员会委员 的议案》，现将相关情况公告如下： 一、调整公司各专门委员会委员 鉴于公司原独立董事陈莹女士任职到期并选举新任独立董事，公司拟对董事 会审计委员会委员、提名委员会委员进行相应调整。调整后的审计委员会委员、 提名委员会委员的任期自董事会审议通过之日起至第九届董事会任期届满之日 止。具体调整情况如下： 1、审计委员会 调整前：张斌（召集人）、陈莹、涂斌 调整后：张斌（召集人）、吴方、涂斌 2、提名委员会 调整前：胡一桥（召集人）、陈莹、钱振华 调整后：胡一桥（召集人）、吴方、钱振华 特此公告。 江苏联环药业股份有限公司董事会 2025 年 8 月 12 日 江苏联环药业股份有限公司 关于调整公司各专门委员会委员的公告 1 ...

证券代码：600513 证券简称：联环药业 公告编号：2025-055 江苏联环药业股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 1、出席会议的股东和代理人人数 | 492 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 119,102,153 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 41.7234 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 8 月 11 日 (二)股东会召开的地点：扬州生物健康产业园健康一路 9 号联环药业会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 本次会议经过适当的召集和通知程序，由公司董事长钱振华先生主持，采用 了现场投票与网络投票相结合的表决方式，符合《中华人民共和国公司法》、中 国证监会《上市 ...